{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:47:29Z","timestamp":1769586449894,"version":"3.49.0"},"reference-count":103,"publisher":"Elsevier","isbn-type":[{"value":"9780443136559","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.ircmb.2024.06.005","type":"book-chapter","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T11:58:06Z","timestamp":1722254286000},"page":"151-175","source":"Crossref","is-referenced-by-count":1,"title":["Advances in metastatic prostate cancer circulating tumor cell enrichment technologies and clinical studies"],"prefix":"10.1016","author":[{"given":"Naira Essam","family":"Abou-Ghali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi","family":"Giannakakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.ircmb.2024.06.005_bib1","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: From discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib2","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncb1725","article-title":"Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells","volume":"10","author":"Al-Nedawi","year":"2008","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib4","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.72.4138","article-title":"Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer","volume":"35","author":"Antonarakis","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1158\/1541-7786.MCR-10-0490","article-title":"Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers","volume":"9","author":"Armstrong","year":"2011","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib7","first-page":"146","article-title":"A case of cancer in which cells similar to those in the tumours were seen in the blood after death","volume":"14","author":"Ashworth","year":"1869","journal-title":"Australasian Medical Journal"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib8","doi-asserted-by":"crossref","first-page":"bqae022","DOI":"10.1210\/endocr\/bqae022","article-title":"Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection","volume":"165","author":"Bae","year":"2024","journal-title":"Endocrinology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2022.08.010","article-title":"Analysis of BRCA2 copy number loss and genomic instability in circulating tumor cells from patients with metastatic castration-resistant prostate cancer","volume":"83","author":"Barnett","year":"2023","journal-title":"European Urology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib10","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"Bono","year":"2008","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12885-015-1383-x","article-title":"High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining","volume":"15","author":"Campton","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41698-022-00289-1","article-title":"Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case","volume":"6","author":"Chai","year":"2022","journal-title":"npj Precision Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pros.22625","article-title":"Single\u2010cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT\u2010related genes in metastatic prostate cancer","volume":"73","author":"Chen","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib14","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1073\/pnas.1718811115","article-title":"Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13","volume":"115","author":"Chen","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib15","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib16","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/PPO.0000000000000220","article-title":"Clinical validity of detecting circulating tumor cells by AdnaTest assay compared with direct detection of tumor mRNA in stabilized whole blood, as a biomarker predicting overall survival for metastatic castration-resistant prostate cancer patients","volume":"22","author":"Danila","year":"2016","journal-title":"The Cancer Journal"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.863472","article-title":"Liquid biopsy based circulating biomarkers in metastatic prostate cancer","volume":"12","author":"Dathathri","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1060864","article-title":"The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer","volume":"12","author":"Davies","year":"2023","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.mtbio.2022.100474","article-title":"RNA profiling of circulating tumor cells systemically captured from diagnostic leukapheresis products in prostate cancer patients","volume":"17","author":"Dong","year":"2022","journal-title":"Materials Today Bio"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib21","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1538-7445.AM2024-6563","article-title":"Abstract 6563: PSMA-based detection and global proteome-based analysis of circulating tumor cells in castration resistant prostate cancer patients","volume":"84","author":"Drake","year":"2024","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237308","article-title":"Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients","volume":"15","author":"Drucker","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.euo.2018.12.005","article-title":"An accessible and unique insight into metastasis mutational content through whole-exome sequencing of circulating tumor cells in metastatic prostate cancer","volume":"3","author":"Faugeroux","year":"2020","journal-title":"European Urology Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/pros.24469","article-title":"A correlative biomarker study and integrative prognostic model in chemotherapy\u2010na\u00efve metastatic castration\u2010resistant prostate cancer treated with enzalutamide","volume":"83","author":"Fernandez\u2010Perez","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.20517\/2394-4722.2017.45","article-title":"Using circulating tumor cells to advance precision medicine in prostate cancer","volume":"3","author":"Galletti","year":"2017","journal-title":"Journal of Cancer Metastasis and Treatment"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib26","doi-asserted-by":"crossref","first-page":"2105530","DOI":"10.1002\/advs.202105530","article-title":"Single\u2010cell RNA\u2010seq reveals a developmental hierarchy super\u2010imposed over subclonal evolution in the cellular ecosystem of prostate cancer","volume":"9","author":"Ge","year":"2022","journal-title":"Advanced Science"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib27","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s42003-021-02321-9","article-title":"Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage","volume":"4","author":"Gjyrezi","year":"2021","journal-title":"Communications Biology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1039\/B917959C","article-title":"Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody","volume":"10","author":"Gleghorn","year":"2009","journal-title":"Lab Chip"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1373\/clinchem.2016.260299","article-title":"Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells","volume":"62","author":"Gorges","year":"2016","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib31","doi-asserted-by":"crossref","first-page":"34930","DOI":"10.18632\/oncotarget.9004","article-title":"Heterogeneous PSMA expression on circulating tumor cells\u2014A potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer","volume":"7","author":"Gorges","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib32","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1016\/j.cell.2023.05.028","article-title":"DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and CTCs","volume":"186","author":"Guo","year":"2023","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33393\/jcb.2024.2636","article-title":"Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer","volume":"13","author":"Gupta","year":"2024","journal-title":"Journal of Circulating Biomarkers"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib34","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/JCO.2020.38.6_suppl.147","article-title":"Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC)","volume":"38","author":"Gupta","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib35","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1158\/1078-0432.CCR-16-1211","article-title":"Whole genomic copy number alterations in circulating tumor cells from men with abiraterone or enzalutamide-resistant metastatic castration-resistant prostate cancer","volume":"23","author":"Gupta","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nature Reviews Urology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib37","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/1078-0432.CCR-23-3017","article-title":"The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide","volume":"30","author":"Halabi","year":"2024","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1158\/0008-5472.CAN-19-3447","article-title":"Shaping chromatin states in prostate cancer by pioneer transcription factors","volume":"80","author":"Hankey","year":"2020","journal-title":"Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nature Clinical Practice Urology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib40","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1038\/ncomms13668","article-title":"Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer","volume":"7","author":"Henzler","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41588-020-0628-z","article-title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","volume":"52","author":"Hu","year":"2020","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib42","first-page":"232","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib43","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/cancers15041307","article-title":"Extracellular vesicles in liquid biopsies as biomarkers for solid tumors","volume":"15","author":"Irmer","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib45","doi-asserted-by":"crossref","first-page":"44781","DOI":"10.18632\/oncotarget.6330","article-title":"A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.594023","article-title":"Cell plasticity-related phenotypes and taxanes resistance in castration-resistant prostate cancer","volume":"10","author":"Jim\u00e9nez","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib47","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/pros.23901","article-title":"Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients","volume":"79","author":"Joncas","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib48","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/9d3d22ed-dc5a-4484-9254-1584864f4aac","article-title":"Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device","volume":"7","author":"Kirby","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib50","doi-asserted-by":"crossref","first-page":"1801254","DOI":"10.1002\/advs.201801254","article-title":"Detection of CTC clusters and a dedifferentiated RNA\u2010expression survival signature in prostate cancer","volume":"6","author":"Kozminsky","year":"2019","journal-title":"Advanced Science"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib51","article-title":"Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients","volume":"6","author":"Kuske","year":"2016","journal-title":"Scientific Reports-UK"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41557-018-0025-8","article-title":"Single-cell mRNA cytometry via sequence-specific nanoparticle clustering and trapping","volume":"10","author":"Labib","year":"2018","journal-title":"Nature Chemistry"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169427","article-title":"Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion","volume":"12","author":"Laget","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","article-title":"Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: A retrospective cohort study","volume":"15","author":"Lalonde","year":"2014","journal-title":"Lancet Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib55","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cyto.a.23507","article-title":"ClearCell\u00ae FX, a label\u2010free microfluidics technology for enrichment of viable circulating tumor cells","volume":"93","author":"Lee","year":"2018","journal-title":"Cytom Part A"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072066","article-title":"Global gene expression characterization of circulating tumor cells in metastasic castration-resistant prostate cancer patients","volume":"9","author":"Le\u00f3n-Mateos","year":"2020","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-19-3023","article-title":"Diverse AR gene rearrangements mediate resistance to androgen receptor inhibitors in metastatic prostate cancer","volume":"26","author":"Li","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt.2892","article-title":"Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer","volume":"32","author":"Lohr","year":"2014","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib59","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11523-015-0396-3","article-title":"Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: An exploratory analysis","volume":"11","author":"Massari","year":"2016","journal-title":"Targeted Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib60","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cyto.a.23571","article-title":"The Parsortix\u2122 Cell Separation System\u2014A versatile liquid biopsy platform","volume":"93","author":"Miller","year":"2018","journal-title":"Cytometry Part A"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib61","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-1406","article-title":"An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer","volume":"8","author":"Miyamoto","year":"2018","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib62","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1126\/science.aab0917","article-title":"RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance","volume":"349","author":"Miyamoto","year":"2015","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib63","first-page":"636","article-title":"Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel","volume":"3","author":"Mukhtar","year":"2020","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib64","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib65","doi-asserted-by":"crossref","first-page":"19283","DOI":"10.18632\/oncotarget.25019","article-title":"Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients","volume":"9","author":"Nanou","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib66","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41416-019-0726-9","article-title":"Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival","volume":"122","author":"Nanou","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib67","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1073\/pnas.1808196115","article-title":"HoxB13 mediates AR-V7 activity in prostate cancer","volume":"115","author":"Navarro","year":"2018","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib68","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/cells8070688","article-title":"Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients: A comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes","volume":"8","author":"Nimir","year":"2019","journal-title":"Cells"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib69","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41391-020-00304-1","article-title":"Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer","volume":"24","author":"Oeyen","year":"2021","journal-title":"Prostate Cancer P D"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib70","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/cncr.31161","article-title":"Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration\u2010resistant prostate cancer (CRPC)","volume":"124","author":"Pal","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib71","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease\u2014Latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib72","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1373\/clinchem.2018.287102","article-title":"Circulating tumor cells in prostate cancer: From discovery to clinical utility","volume":"65","author":"Pantel","year":"2019","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib73","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/cancers13112795","article-title":"Cell plasticity and prostate cancer: The role of epithelial\u2013mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance","volume":"13","author":"Papanikolaou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib74","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib75","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41416-021-01610-8","article-title":"Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: A decade of research","volume":"126","author":"Ramirez-Garrastacho","year":"2022","journal-title":"British Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib76","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/cells9081863","article-title":"Genomic analysis of localized high-risk prostate cancer circulating tumor cells at the single-cell level","volume":"9","author":"Rangel-Pozzo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib77","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.eururo.2016.08.012","article-title":"The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients","volume":"71","author":"Re","year":"2017","journal-title":"European Urology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/bju.14792","article-title":"Androgen receptor (AR) splice variant 7 and full\u2010length AR expression is associated with clinical outcome: A translational study in patients with castrate\u2010resistant prostate cancer","volume":"124","author":"Re","year":"2019","journal-title":"BJU International"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib79","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fonc.2020.00582","article-title":"New screening test improves detection of prostate cancer using circulating tumor cells and prostate-specific markers","volume":"10","author":"Ried","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib80","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","article-title":"Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the cell search system","volume":"13","author":"Riethdorf","year":"2007","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112533","article-title":"Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer","volume":"42","author":"Saini","year":"2023","journal-title":"Cell Reports"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib82","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdm583","article-title":"Circulating tumor cells in colorectal cancer: Correlation with clinical and pathological variables","volume":"19","author":"Sastre","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib84","article-title":"Circulating and imaging biomarkers of radium-223 response in metastatic castration-resistant prostate cancer","volume":"8","author":"Saylor","year":"2024","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2021.02.042","article-title":"Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer","volume":"150","author":"Scher","year":"2021","journal-title":"European Journal of Cancer"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib86","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/jamaoncol.2018.1621","article-title":"Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer","volume":"4","author":"Scher","year":"2018","journal-title":"JAMA Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib87","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.eururo.2016.11.024","article-title":"Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer","volume":"71","author":"Scher","year":"2017","journal-title":"European Urology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib88","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib89","doi-asserted-by":"crossref","first-page":"72755","DOI":"10.18632\/oncotarget.20346","article-title":"Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1\/PD-L1 inhibitors in early and metastatic solid tumors","volume":"8","author":"Schott","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib90","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib91","doi-asserted-by":"crossref","DOI":"10.1158\/1541-7786.MCR-17-0539","article-title":"Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature","volume":"16","author":"Singhal","year":"2018","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib92","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"Skog","year":"2008","journal-title":"Nature Cell Biology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib93","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.21.00169","article-title":"Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistance mechanisms in metastatic prostate cancer","volume":"39","author":"Sperger","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib94","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/1078-0432.CCR-16-1021","article-title":"Integrated analysis of multiple biomarkers from circulating tumor cells enabled by exclusion-based analyte isolation","volume":"23","author":"Sperger","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib95","article-title":"Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY","volume":"25","author":"Tagawa","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9440(10)64706-2","article-title":"Isolation by size of epithelial tumor cells a new method for the immunomorphological and molecular characterization of circulating tumor cells","volume":"156","author":"Vona","year":"2000","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5772\/60725","article-title":"Analytical validation and capabilities of the epic CTC platform: Enrichment-free circulating tumour cell detection and characterization","volume":"4","author":"Werner","year":"2015","journal-title":"Journal of Circulating Biomarkers"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib44","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib98","doi-asserted-by":"crossref","DOI":"10.1088\/1478-3975\/ab073a","article-title":"Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients","volume":"16","author":"Worroll","year":"2019","journal-title":"Physical Biology"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib99","article-title":"Classification of circulating tumor cells by epithelial-mesenchymal transition markers","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib100","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bju.14642","article-title":"Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration\u2010sensitive prostate cancer","volume":"124","author":"Yang","year":"2019","journal-title":"BJU International"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib101","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1021\/acs.analchem.7b03536","article-title":"Molecular profiling of pooled circulating tumor cells from prostate cancer patients using a dual-antibody-functionalized microfluidic device","volume":"90","author":"Yin","year":"2018","journal-title":"Analytical Chemistry"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib102","doi-asserted-by":"crossref","unstructured":"Zhang, J., Zimmermann, B., Galletti, G., Halabi, S., Gjyrezi, A., Yang, Q., ... Giannakakou, P. (2021). Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer. Medrxiv.","DOI":"10.1101\/2021.11.01.21265757"},{"key":"10.1016\/bs.ircmb.2024.06.005_bib103","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40364-021-00267-y","article-title":"Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomarker Research"}],"container-title":["International Review of Cell and Molecular Biology","Circulating Tumor Cells, From Biotech Innovation to Clinical Utility - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193764482400100X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193764482400100X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T16:20:03Z","timestamp":1745511603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193764482400100X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443136559"],"references-count":103,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2024.06.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}